This time expect a revenue growth of 15 percent odd for Glenmark Pharma with EBITDA growth of around 36 percent. So there should be some amount of an improvement in the margins on a year-on-year (YoY) basis to 17.4 versus 14.6 percent with the profit at around Rs 225 crore odd. However, the profit is going to be aided by low base because the profit was down 75 percent same time last year.
